Verastem Oncology Data From TARGET-D 101 Phase 1/2 Clinical Study Of VS-7375 Shows Encouraging Clinical Activity Including Favorable Safety Profile; Broad Anti-Tumor Activity Observed

Loading news article.

Verastem Oncology Data From TARGET-D 101 Phase 1/2 Clinical Study Of VS-7375 Shows Encouraging Clinical Activity Including Favorable Safety Profile; Broad Anti-Tumor Activity Observed | WAPE

Verastem Oncology Data From TARGET-D 101 Phase 1/2 Clinical Study Of VS-7375 Shows Encouraging Clinical Activity Including Favorable Safety Profile; Broad Anti-Tumor Activity Observed

Article summary

Related companies

Comments —